Early clinical data continued to challenge the idea that CAR-T is limited mainly to hematologic cancers, with a Phase 1 report in relapsed/refractory multiple myeloma showing responses across all treated participants. The update provides a benchmark for next-generation CAR-T durability and safety in a disease with known immune escape mechanisms. Separately, ongoing review-level work is mapping how solid-tumor CAR-T may be engineered for safer activity, including biomarker strategies and manufacturing economics. While reviews don’t establish new efficacy by themselves, they reflect what trial designers are converging on for translation: dose control, target selection, and process scale. Taken together, the coverage points to a broader clinical priority—pushing CAR-T into harder tumor contexts while tightening engineering and cost levers to support wider access.